<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The detection of Philadelphia-negative (Ph(neg)) cells with non-random karyotypic abnormalities after <z:chebi fb="0" ids="38637">tyrosine kinase inhibitor</z:chebi> (TKI) therapy of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:mp ids='MP_0005481'>CML</z:mp>) can be associated with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>To our knowledge, however, there have been no studies on variables influencing the risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in patients with specific Ph(neg) karyotypes </plain></SENT>
<SENT sid="2" pm="."><plain>We systematically examined studies reporting -7 or del(7q) within Ph(neg) cells in TKI-treated <z:mp ids='MP_0005481'>CML</z:mp> patients, and abstracted clinical and cytogenetic data from individual reports into a standardized format for further analysis </plain></SENT>
<SENT sid="3" pm="."><plain>Of 53 patients, 43 had Ph(neg) -7 clones [as the sole abnormality (-7(sole)) in 29, or with other clones (-7(dual)) in 14], and del(7q) was present in 10 </plain></SENT>
<SENT sid="4" pm="."><plain>A total of 16/51 evaluable patients, <z:hpo ids='HP_0000001'>all</z:hpo> with -7, transformed to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Transformation was more frequent (15/16 patients) within 6 months of Ph(neg) -7 detection rather than subsequently (P &lt; 0.0001) </plain></SENT>
<SENT sid="6" pm="."><plain>At first detection after TKI therapy, Ph(neg) abnormal clones comprised â‰¥50% of Ph(neg) cells in a greater proportion of patients with -7 than del(7q) (P = 0.035) </plain></SENT>
<SENT sid="7" pm="."><plain>Upon comparing -7(sole) and -7(dual), the latter was likely to be transient (P = 0.004), and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> was frequently observed with persistent -7 clones (P = 0.03) </plain></SENT>
<SENT sid="8" pm="."><plain>By logistic regression analysis (n = 36), clone size (P = 0.017), time-to-detection longer than 15 months (P = 0.02), and <z:mp ids='MP_0005481'>CML</z:mp> response (P = 0.085) were associated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Validation of these novel associations in registry-based studies will help develop predictive criteria that define the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> risk in individual patients </plain></SENT>
</text></document>